Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT01015222
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dasatinib — DRUG
    Starting dose of 50 mg daily PO for 28 day cycle
  • Bevacizumab — DRUG
    Starting dose 5 mg/kg IV Day 1 and 15
  • Paclitaxel — DRUG
    Starting dose 40 mg/m2 IV Day 1, 8 and 15

Study Details

The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Key Dates

First listed
Nov 18, 2009
Start date
Nov 30, 2009
Status verified
Nov 2022
Primary completion
May 27, 2021
Completion
May 27, 2021

Study Design

Enrollment
122 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dasatinib, Bevacizumab + Paclitaxel
    Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15 Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment [ Time Frame: Continuous assessment during each dose level/28-day cycle ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies